Beta-2 microglobulin-deficient cells
US11813318B2 · kind B2 · utility
0Cited by
11References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2019 |
| Grant date | Nov 14, 2023 |
| Priority date | — |
| Expiry date | Jul 30, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.